[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-hematopoietic-stem-cell-transplantation-recipient\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-hematopoietic-stem-cell-transplantation-recipient":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,69,109,137,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100642409","efficacy-and-safety-of-the-clob2m-clofarabine-combined-with-busulfan-and-melphalan-conditioning-regimen-in-allogeneic-hematopoietic-stem-cell-transplantation-for-adult-patients-with-acute-myeloid-leukemia-in-first-complete-remission-100642409",false,"NCT07644481","Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission","Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Prospective, Single-Arm Clinical Trial","Inclusion Criteria:\n\n* 1.Aged from 18 to 60 years inclusive, with no restriction on gender;\n* 2.Patients diagnosed with acute myeloid leukemia (AML, excluding acute promyelocytic leukemia, APL) by bone marrow morphological, immunological and genetic examinations according to the 2022 World Health Organization (WHO) classification, who have achieved first complete remission (CR1) after induction therapy;\n* 3.Meeting any of the following criteria upon clinical evaluation:\n\n  1. AML classified as intermediate or adverse genetic risk according to the 2022 ELN genetic risk stratification;\n  2. AML with positive measurable residual disease (MRD) before transplantation;\n* 4.Eastern Cooperative Oncology Group Performance Status (ECOG PS): 0-2;\n* 5.Estimated survival time more than 6 months;\n* 6.Meeting the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT), and having an eligible hematopoietic stem cell donor with qualified physical examination, including HLA-matched sibling donor, unrelated donor (high-resolution HLA 9-10\u002F10 matched) or haploidentical related donor;\n* 7.Adequate major organ function meeting the following criteria:\n\n  1. Total bilirubin (TBIL) ≤ 2 times the upper limit of normal (ULN); Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3 × ULN;\n  2. Serum creatinine (Cr) ≤ 1.5 × ULN, or estimated creatinine clearance ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault glomerular filtration formula;\n  3. Coagulation function meeting the following standards: Prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN (without anticoagulant therapy);\n  4. Electrocardiogram showing no acute myocardial infarction or severe arrhythmia; Echocardiography with left ventricular ejection fraction (LVEF) ≥ 50%, without significant cardiomegaly, valvular heart disease or congenital heart disease;\n  5. Pulmonary function tests: FEV1, FVC and DLCO ≥ 60% of predicted value;\n* 8.Willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy prior to study treatment, and agree to receive regular bone marrow aspiration and biopsy after study treatment;\n* 9.Must sign the informed consent form prior to study enrollment, signed by the patient personally or immediate family members. If signature by the patient is deemed detrimental to disease treatment based on clinical condition assessment, the informed consent shall be signed by the legal guardian or immediate family member of the patient.\n\nExclusion Criteria:\n\n* 1.Refractory\u002Frelapsed AML;\n* 2.Known hypersensitivity to any drugs in the conditioning regimen or their excipients;\n* 3.Major surgery within the past 4 weeks (excluding diagnostic surgical procedures);\n* 4.History of or concurrent other malignant tumors (excluding well-controlled non-melanoma basal cell carcinoma of the skin, breast\u002Fcervical carcinoma in situ, and other malignancies well controlled without treatment for more than five years);\n* 5\\. Uncontrolled systemic diseases (such as uncontrolled hypertension, diabetes mellitus, etc.);\n* 6.Active hepatitis B or hepatitis C infection:（Hepatitis B virus surface antigen positive, hepatitis B core antibody positive with HBV-DNA level exceeding 1×103 copies\u002FmL;Hepatitis C virus RNA level exceeding 1×10 3 copies\u002FmL）;\n* 7.Uncontrolled ongoing infection, or patients requiring mechanical ventilation or with hemodynamic instability;\n* 8.Patients with psychiatric disorders or other medical conditions who are unable to comply with study treatment and monitoring requirements;\n* 9.Participation in another ongoing clinical trial, or enrollment in any other drug clinical trial within the past 1 month;\n* 10.Pregnant or lactating females, and patients who refuse to use effective contraception during the study period;\n* 11.Patients who are unable to understand the trial protocol, adhere to medication instructions, or refuse to sign the informed consent form;\n* 12.Patients deemed ineligible for enrollment by the investigator.","ALL","18 Years","60 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center, prospective, exploratory clinical study. It plans to enroll 30 adult patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR1) after induction therapy and meet the indications for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The aim is to evaluate the efficacy and safety of allo-HSCT following conditioning regimens with clofarabine, busulfan and melphalan.",[27,28],"AML (Acute Myelogenous Leukemia)","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","NOT_YET_RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":21},"2026-07-20",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100640492","phase-2-vabu-conditioning-in-elderly-aml-hsct-100640492","NCT07583888","VABu Conditioning in Elderly AML HSCT","Efficacy and Safety of the VABu Conditioning Regimen in Elderly Patients With Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter, Single-Arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 60 years.\n2. Confirmed diagnosis of acute myeloid leukemia (AML) according to WHO classification, with intermediate or high-risk prognosis.\n3. Previous response to Venetoclax-based therapy.\n4. Planned to undergo allogeneic hematopoietic stem cell transplantation (HSCT).\n5. Donor availability: Related donor matched at least 5\u002F10 at HLA-A, -B, -C, -DQB1, and -DRB1; OR unrelated donor matched at least 8\u002F10 at the same loci.\n6. Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score ≤ 4.\n7. ECOG performance status 0-2.\n8. Adequate organ function as defined by: Creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 45 mL\u002Fmin (Cockcroft-Gault formula or 24-hour urine collection)； AST ≤ 3.0 × ULN and ALT ≤ 3.0 × ULN； Total bilirubin ≤ 1.5 × ULN； Left ventricular ejection fraction (LVEF) \\> 50%； Baseline oxygen saturation \\> 92%； DLCO ≥ 40% and FEV1 ≥ 50%；\n9. Ability to understand and provide written informed consent.\n\nExclusion Criteria:\n\n1. Age \\\u003C 60 years.\n2. Poor response to prior Venetoclax-based therapy.\n3. Unstable systemic disease (unstable angina, myocardial infarction, cerebrovascular accident within 3 months; NYHA Class III-IV heart failure; severe arrhythmia; pulmonary hypertension).\n4. Active uncontrolled infection or active bleeding in vital organs.\n5. CNS symptoms grade ≥ 2 requiring treatment.\n6. Major organ surgery within 6 weeks.\n7. History of malignant disease other than AML within 5 years.\n8. History of thrombosis, embolism, or cerebral hemorrhage within 1 year.\n9. ECOG performance status \\> 2.\n10. HCT-CI score \\> 4.\n11. Organ failure meeting specified criteria.\n12. Known HIV, active HBV, or active HCV infection.\n13. History of autoimmune disease requiring systemic immunosuppressive therapy.\n14. Pregnancy, breastfeeding, or unwillingness to use effective contraception in patients of childbearing potential.\n15. Drug abuse or chronic alcoholism.\n16. Psychiatric disorder or other condition compromising informed consent or compliance.\n17. Any other condition making the patient unsuitable for study participation in the investigator's judgment.",{"count":49,"type":21},20,[51,52],"PHASE2","PHASE3","This is an open-label, multi-center, single-arm clinical study evaluating the efficacy and safety of the VABu conditioning regimen in elderly patients (≥60 years) with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT).\n\nThe VABu regimen consists of Venetoclax, Azacitidine, Semustine, Cytarabine, and Busulfan. All enrolled participants will receive the VABu regimen as conditioning therapy prior to HSCT.\n\nThe study aims to enroll 20 participants from multiple centers in China. The primary objectives are to evaluate the overall response rate, cumulative relapse rate, overall survival, graft-versus-host disease (GVHD)-free relapse-free survival (GRFS), non-relapse mortality (NRM), incidence of acute and chronic GVHD, and reactivation rates of cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Safety outcomes include treatment-related toxicities, such as bone marrow suppression, infection, and organ dysfunction.",[28,55],"Acute Myeloid Leukemia (AML)",[57],"Acute Myeloid Leukemia; Elderly; Hematopoietic Stem Cell Transplantation; Venetoclax; Busulfan; Preconditioning","RECRUITING","2026-05-12",{"date":61,"type":33},"2026-05-14",{"date":63,"type":21},"2026-05-07",{"date":65,"type":21},"2027-08-15",{"name":67,"class":40},"The First Affiliated Hospital of Soochow University",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100345603","phase-2-naive-t-cell-depletion-for-preventing-chronic-graft-versus-host-disease-in-children-and-young-adults-with-blood-cancers-undergoing-donor-stem-cell-transplant-100345603","NCT03779854","Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults","Inclusion Criteria:\n\n* The patient must have one of the following diagnoses and be considered to be an appropriate candidate for allogeneic HCT by the study site principal investigator (PI):\n\n  * Acute lymphoblastic leukemia (ALL) with \\\u003C 5% marrow blasts.\n  * Acute myeloid leukemia (AML) with \\\u003C 25% marrow blasts.\n  * Other acute leukemia (OAL) or related neoplasm (including but not limited to acute biphenotypic leukemia \\[ABL\\], ambiguous lineage \\[ALAL\\], mixed phenotype acute leukemia \\[MPAL\\], blastic plasmacytoid dendritic cell neoplasm \\[BPDCN\\], acute undifferentiated leukemia \\[AUL\\], lymphoblastic lymphoma, Burkitt leukemia\u002Flymphoma, mast cell leukemia, chronic monocytic leukemia \\[CML\\] with blast crisis or other chronic myeloproliferative neoplasm) with \\\u003C 5% marrow blasts.\n  * Myelodysplastic syndrome (MDS) with excess blasts (EB-1 and EB-2) and has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)\n* Age 6 months to 26 years at the time informed consent is obtained using the Informed Consent to Participate in a Research Study form\n* Matched related donor (MRD) or matched unrelated donor (MUD) (defined as 8\u002F8 match for human leukocyte antigen \\[HLA\\]-A, -B, -C, -DRB1).\n* Planned product type for infusion is PBSC or BM (i.e. not cord blood):\n\n  * For feasibility phase, planned product type for infusion must be PBSC.\n  * For RCT, planned product type must be PBSC or BM.\n* Karnofsky or Lansky score \\>= 60%.\n* Left ventricular ejection fraction (LVEF) at rest \\>= 40%.\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) \\>= 60% predicted by pulmonary function tests (PFTs)\n\n  \\* Patients who are unable to perform PFTs (age \\\u003C 6 years or considered developmentally incapable of PFTs): oxygen saturation (by oximetry) must be \\>= 92% on room air.\n* Total bilirubin =\\\u003C 2 x upper limit of normal (ULN) (unless value\\[s\\] \\> 2 x ULN are disease- or medication-related).\n\n  \\* If value(s) are \\> 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal (GI) physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.\n* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =\\\u003C 2 x ULN (unless value\\[s\\] \\> 2 x ULN are disease- or medication-related).\n\n  \\* If value(s) are \\> 2 x ULN and not disease- or medication related, patient must be evaluated by a gastrointestinal GI physician. If GI physician considers protocol treatment to be contraindicated for the patient, the patient will not be eligible for the study.\n* Serum creatinine (SCr) within normal range for age. If SCr is outside normal range for age, creatinine clearance (CrCl) \\> 40 mL\u002Fmin\u002F1.73m\\^2 must be obtained (measured by 24-hour \\[hr\\] urine specimen or nuclear glomerular filtration rate \\[GFR\\]).\n\n  * Age (Years): Maximum SCr (mg\u002FdL)\n  * =\\\u003C 5: 0.8\n  * 6-10: 1\n  * 11-15: 1.2\n  * \\> 15: 1.5\n* Recipient informed consent\u002Fassent\u002Flegal guardian permission documentation must be obtained.\n* DONOR: May be related (MRD) or unrelated (MUD) to the subject.\n* DONOR: Must be matched to the subject at 8\u002F8 HLA alleles (HLA-A, -B, -C, and -DRB1)\n* DONOR: Be \\>=14 years of age.\n* DONOR: Must be available to donate in the United States of America (USA) (i.e. excludes international donors).\n* DONOR: Must agree to donate BM or PBSC (i.e. agree to donate whichever product type is requested) (applicable only to the RCT phase of this study).\n* DONOR: MUDs:\n\n  * Must give informed consent according to applicable National Marrow Donor Program (NMDP) donor regulatory requirements\n  * Must meet eligibility criteria as defined by the NMDP or be ineligible with statement of urgent medical need (exception 21 CFR 1271.65(b)(iii))\n\n    * Tests must be performed using Food and Drug Administration (FDA) licensed, cleared, and approved test kits in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory\n* DONOR: MRDs:\n\n  * Must be negative for human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2, hepatitis B, hepatitis C (serological and\u002For nucleic acid testing \\[NAT\\] and\u002For other approved testing)\n  * Must meet institutional donor eligibility criteria, or be ineligible with statement that the donor is a first or second degree relative (exception 21 CRF 1271.65(b)(i)).\n\n    * Tests must be performed using FDA licensed, cleared, and approved test kits in a CLIA-certified laboratory.\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) disease. A patient may have a history of CNS disease; however, any CNS disease must be cleared by the end of the pre-conditioning evaluation. If CNS disease is identified on the first cerebrospinal fluid (CSF) evaluation within 30 days of the start of the preparative regimen, a repeat CSF evaluation must be performed and show no evidence of disease in order for the patient to be eligible for the protocol.\n* Patients on other experimental protocols for the prevention of GVHD.\n* Patient body weight:\n\n  * Matched related donor (MRD): \\> 100 kg are ineligible\n  * Matched unrelated donor (MUD): \\> 75 kg must be discussed with the protocol principal investigator (PI) prior to enrollment.\n* HIV-positive.\n* Uncontrolled infections must be evaluated by an infectious disease physician and considered suitable to undergo HCT by the study site PI, infectious disease physician and protocol PI. Upper respiratory tract infection (URI) does not constitute an uncontrolled infection in this context.\n* Life expectancy \\\u003C 3 months from disease other than acute leukemia or myelodysplastic syndrome (MDS).\n* Significant medical condition that would make recipient unsuitable for HCT.\n* Prior allogeneic or autologous HCT.\n* Females who are pregnant or breastfeeding.\n* Patients of child bearing age who are presumed to be fertile and are unwilling to use an effective birth control method or refrain from sexual intercourse during study treatment and for 12 months following HCT.\n* Known hypersensitivity to tacrolimus, fludarabine, or methotrexate (MTX).",true,"6 Months","26 Years",{"count":80,"type":21},68,[51],"This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.",[84,85,86,87,88,28,89,90,91,92,93,94,95,96,97,98,99],"Acute Biphenotypic Leukemia","Acute Leukemia","Acute Leukemia of Ambiguous Lineage","Acute Lymphoblastic Leukemia","Acute Undifferentiated Leukemia","Blastic Plasmacytoid Dendritic Cell Neoplasm","Blasts Under 25 Percent of Bone Marrow Nucleated Cells","Blasts Under 5 Percent of Bone Marrow Nucleated Cells","Mixed Phenotype Acute Leukemia","Myelodysplastic Syndrome With Excess Blasts-1","Myelodysplastic Syndrome\u002FAcute Myeloid Leukemia","Burkitt Leukemia","Chronic Monocytic Leukemia","Lymphoblastic Lymphoma","Mast Cell Leukemia","Myeloproliferative Neoplasm","2026-05-11",{"date":61,"type":33},{"date":103,"type":33},"2019-08-29",{"date":105,"type":21},"2028-12-31",{"name":107,"class":40},"Fred Hutchinson Cancer Center",10,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":76,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100336842","early-phase-1-donor-virus-specific-cmv-or-adv-ctl-to-treat-cmv-or-adv-reactivation-or-disease-after-solid-organ-or-hct-100336842","NCT03665675","Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT","Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)","Inclusion Criteria:\n\n* Patients must have solid organ transplant or have received allogeneic hematopoietic stem cell transplant.\n* • Cohort A (CMV): Must have documented CMV disease or reactivation, as by:\n\n  * Viremia as detected by quantitative polymerase chain reaction (PCR) (\\> 500 IU\u002Fml) in the peripheral blood requiring treatment OR\n  * High risk for antiviral failure due to history of recurrent CMV reactivations or evidence of antiviral drug resistance, OR\n  * Unable to tolerate antiviral drugs due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury\n\n    • Cohort B (AdV): Must have documented AdV infection or reactivation, as by:\n  * Symptomatic subject with any detectable viral load in blood, OR\n  * Symptomatic subject with qualitative AdV detection in compartment of current symptomatology, including stool, urine, and\u002For other specimens (bronchoalveolar lavage (BAL), nasal swab, CSF, etc.), irrespective of blood viral load, OR\n  * New, persistent, and\u002For worsening AdV-related symptoms, signs, and\u002For markers of end organ compromise while receiving antiviral therapy (ie cidofovir), OR\n  * Asymptomatic with a viral load \\> 1000 copies\u002Fml in peripheral blood, OR\n  * Unable to tolerate antiviral treatment due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury\n\n    * Karnofsky (age \\> 16 years) or Lansky performance score \\> 70 (age \\\u003C 16)\n    * Available seropositive haploidentical or matched donor who is without evidence of infection that would otherwise preclude donation\n    * Negative pregnancy test in female patients if applicable (childbearing potential, has not received a full-intensity conditioning regimen\n    * Written informed consent and\u002For signed assent line from patient, parent or guardian\n    * DONOR\n    * Human leukocyte antigen (HLA)-haploidentical or full-match to the patient as determined by institutional standards\n    * Cohort A: CMV seropositive, defined as detection of serum CMV immunoglobulin G (IgG)\n    * Cohort B: AdV seropositive, defined as detection of serum AdV IgG\n    * Age 18 or over\n    * Meet donor eligibility or suitability according to institutional standards. If the donor is deemed ineligible according to Foundation for the Accreditation of Cellular Therapy (FACT) standards, but is suitable for donation per institutional standards, the donor will be eligible for the protocol\n\nExclusion Criteria:\n\n* Receipt of anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell depleting agents within 21 days of screening for enrollment.\n* Receipt of \\> 0.5mg\u002Fkg\u002Fday of prednisone or steroid equivalent at the time of enrollment. Stable GVHD is permitted as long as patients are on stable dose steroids of less than or equal to 0.5 mg\u002Fkg\u002Fday of prednisone or steroid equivalent.\n* Evidence of uncontrolled infection as follows:\n\n  * Bacterial infections - patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.\n  * Fungal infections - patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.\n  * Patients with hemodynamic instability attributable to bacterial sepsis or new symptoms, worsening physical signs or radiographic findings attributable to concomitant bacterial or fungal infection are excluded. Patients who require ventilator support for CMV pneumonitis are not excluded. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n* Receipt of donor lymphocyte infusion (DLI) within 28 days.\n* Patients with active acute graft versus host disease (GvHD) grades II-IV requiring \\> 0.5 mg\u002Fkg\u002Fday of prednisone or steroid equivalent or T-cell depleting immunosuppression.\n* Acute graft rejection in solid organ transplantation requiring augmented immunosuppression with T-cell depleting agents or steroids as mentioned above.\n* Active and uncontrolled relapse of malignancy.","1 Year","85 Years",{"count":49,"type":21},[120],"EARLY_PHASE1","This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \\[CMV\\] specific cytotoxic T-lymphocytes \\[CTLs\\]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific \\[AdV\\] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.",[28,123,124,125,126],"Cytomegalovirus","Donor","Solid Organ Transplantation Recipient","Adenovirus","2026-04-10",{"date":129,"type":33},"2026-04-15",{"date":131,"type":33},"2020-11-07",{"date":133,"type":21},"2026-12-20",{"name":135,"class":40},"Sumithira Vasu",2,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":68},"100619213","prehabilitation-for-patients-diagnosed-with-blood-cancer-and-treated-with-al-logeneic-hematopoietic-stem-cell-transplantation-100619213","NCT07341698","Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation","Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Alloge-neic Hematopoietic Stem Cell Transplantation - a National Randomized Controlled Trial","PrepAllo","Inclusion Criteria:\n\nAdult patients \\>18 years will be eligible for inclusion if they are scheduled for a allo-HSCT with at least four weeks before their scheduled transplantation date.\n\nExclusion Criteria:\n\n* pregnancy\n* physical or mental disabilities precluding test of muscle function\n* inability to read and understand Danish or English",{"count":146,"type":21},110,[24],"Seventy-five percent of patients treated with hematopoietic stem cell transplants survive one-year post-transplantation. However, this intensive treatment is associated with prolonged hospitalizations and significant deconditioning. Pathophysiological changes in skeletal muscle mass and function have notable implications for disease progression and long-term prognosis. Patients frequently report substantial rehabilitation needs, though these needs are highly individualized and fluctuate over time, with musculoskeletal dysfunction and fa-tigue being the most common barriers to prehabilitation. Furthermore, at least 35% of cancer patients are found to have inadequate daily protein intake, which may hinder improve-ments in physical performance through prehabilitation. Several recent studies have demonstrated the safety and feasibility of exercise-based prehabilitation interventions during the pre-transplant period. However, no full-scale randomized controlled trial (RCT) has been conducted to date.",[28],[151,152,153,154],"Prehabilitation","Exercise","resistance training","nutritional support","2026-01-27",{"date":157,"type":33},"2026-01-29",{"date":159,"type":33},"2026-01-12",{"date":161,"type":21},"2032-10-12",{"name":163,"class":40},"Rigshospitalet, Denmark",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":68},"100614966","viromarkers-ga-n101194735---cmv-and-ttv-biomarkers-study-protocol-100614966","NCT07286461","VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol","Inclusion Criteria:\n\n* Be \\> 18 years of age\n* Sign an informed consent\n* HSCT recipients seropositive to CMV, or receiving HSCs from a CMV seropositive donor\n* Antiviral prophylaxis with letermovir for preventing CMV infection will be administered for 100 days in Italy (or 200 days in Germany) after HSCT to all participants according to the current guidelines\n\nExclusion Criteria:\n\nIndividuals \\\u003C18 years old undergoing HSCT Individuals not receiving letermovir prophylaxis",{"count":171,"type":21},290,"OBSERVATIONAL","The study is one of the researches carried out in the VIROMARKERS Project.\n\nThe project VIROMARKERS is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194735. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, Vaccines Europe, and Roboscreen.\n\nTo date, the virological surveillance for CMV replication relies basically on the quantification of CMV-DNA in blood or plasma by using Real-Time PCR assays, and CMV-DNAemia is known to correlate with both CMV-related disease and non-relapse mortality \\[Ljungman, 2025\\]. However, the detection of CMV-DNAemia is not always associated with an active CMV replication, particularly in patients exposed to letermovir. Therefore, the identification of new virological markers to accurately monitor CMV activity in the early and late post-HSCT phases, remains a crucial issue especially in individuals receiving letermovir as prophylaxis to ensure a proper diagnosis of CMV infection\u002Fdisease and to guide prophylactic and pre-emptive antiviral treatment.\n\nIn this setting, the quantification of CMV-RNA represents a potential candidate marker capable of better reflecting the presence of complete, infectious CMV virions than CMV-DNAemia. Despite several data support a correlation of CMV UL21.5-mRNA with viral activity \\[Nicastro, 2025\\], studies investigating the kinetics of this viral mRNA among immune-suppressed patients at risk of CMV re-uptake are largely missing, especially in the setting of patients receiving antiviral prophylaxis with letermovir after HSCT.\n\nTTV-DNA load was mostly investigated in solid organ transplant patients (SOT), where it showed a good correlation of high viral load and degree of immunosuppression. In HSCT patients the interaction of the immune system, which is under reconstitution, and clinically relevant CMV infection is more complex. First data have been reported by our group \\[Gilles et al., 2017\\] showing high TTV load as a prognostic marker for risk of complications after HSCT. Little information is available for HSCT patients under letermovir prophylaxis.\n\nSpecific primary objectives related to CMV monitoring in the HSCT setting are the following:\n\nPrimary In participants who received HSCT, to estimate the rate of initiation of anti-CMV therapy during letermovir-based prophylaxis and the rate of CMV re-activation (based on symptoms, signs of organ dysfunction and CMV-DNAemia) after suspension of letermovir.\n\nTo evaluate the kinetics of CMV-RNAemia, CMV-DNAemia and TTV-DNAemia and their correlation during prophylaxis with letermovir.\n\nTo establish whether early quantitative CMV-RNA level or the early kinetics of CMV-RNAemia and TTV-DNAemia during prophylaxis can predict initiation of anti-CMV therapy.\n\nIn participants not initiating anti-CMV therapy during prophylaxis, to establish whether quantitative CMV-RNA level at time of letermovir suspension or the kinetics of CMV-RNAemia and TTV-DNAemia during prophylaxis can predict CMV re-activation (based on symptoms signs of organ dysfunction and CMV-DNAemia) after suspension of letermovir.\n\nSecondary objectives include to establish a cut-off for CMV-RNAemia and TTV DNAemia to maximize the accuracy of prediction of CMV re-activation after suspension of prophylaxis; to explore the kinetics of CMV-RNAemia and TTV-DNAemia in participants treated with anti CMV drugs.\n\nThe information used from this study on participants in the HSCT setting will be rapidly analyzed and shared broadly to guide policymakers for the use and monitoring of CMV-DNAemia, CMV-RNAemia and TTV-DNAemia in CMV disease and to design future studies. For exact plans regarding the expected date of study completion and plans for dissemination please refer to separate documents produced within the WP5 of VIROMARKERS.",[28,175],"CMV",[175,177],"TTV","2025-12-02",{"date":180,"type":33},"2025-12-16",{"date":182,"type":21},"2025-12-15",{"date":184,"type":21},"2027-12-30",{"name":186,"class":40},"University of Rome Tor Vergata"]